Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 2
1966 2
1978 2
1979 3
1980 2
1981 2
1982 3
1983 6
1984 5
1985 4
1986 15
1987 11
1988 7
1989 2
1990 3
1991 2
1992 5
1993 12
1994 8
1995 8
1996 10
1997 9
1998 9
1999 13
2000 9
2001 13
2002 12
2003 11
2004 13
2005 9
2006 6
2007 7
2008 7
2009 6
2010 8
2011 9
2012 15
2013 8
2014 6
2015 17
2016 17
2017 15
2018 12
2019 22
2020 44
2021 29
2022 33
2023 30
2024 43
2025 41
2026 11

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

564 results

Results by year

Filters applied: . Clear all
Page 1
Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial.
Nakachi K, Ikeda M, Konishi M, Nomura S, Katayama H, Kataoka T, Todaka A, Yanagimoto H, Morinaga S, Kobayashi S, Shimada K, Takahashi Y, Nakagohri T, Gotoh K, Kamata K, Shimizu Y, Ueno M, Ishii H, Okusaka T, Furuse J; Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology Group (JCOG-HBPOG). Nakachi K, et al. Among authors: morinaga s. Lancet. 2023 Jan 21;401(10372):195-203. doi: 10.1016/S0140-6736(22)02038-4. Lancet. 2023. PMID: 36681415 Clinical Trial.
Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01).
Uesaka K, Boku N, Fukutomi A, Okamura Y, Konishi M, Matsumoto I, Kaneoka Y, Shimizu Y, Nakamori S, Sakamoto H, Morinaga S, Kainuma O, Imai K, Sata N, Hishinuma S, Ojima H, Yamaguchi R, Hirano S, Sudo T, Ohashi Y; JASPAC 01 Study Group. Uesaka K, et al. Among authors: morinaga s. Lancet. 2016 Jul 16;388(10041):248-57. doi: 10.1016/S0140-6736(16)30583-9. Epub 2016 Jun 2. Lancet. 2016. PMID: 27265347 Clinical Trial.
A pancreatic cancer organoid incorporating macrophages reveals the correlation between the diversity of tumor-associated macrophages and cancer cell survival.
Tabe S, Takeuchi K, Aoshima K, Okumura A, Yamamoto Y, Yanagisawa K, Eto R, Matsuo M, Ueno Y, Konishi T, Furukawa Y, Yamaguchi K, Morinaga S, Miyagi Y, Ohtsuka M, Tanimizu N, Taniguchi H. Tabe S, et al. Among authors: morinaga s. Biomaterials. 2025 Mar;314:122838. doi: 10.1016/j.biomaterials.2024.122838. Epub 2024 Sep 18. Biomaterials. 2025. PMID: 39348736 Free article.
Randomized phase II trial of chemoradiotherapy with S-1 versus combination chemotherapy with gemcitabine and S-1 as neoadjuvant treatment for resectable pancreatic cancer (JASPAC 04).
Sugiura T, Toyama H, Fukutomi A, Asakura H, Takeda Y, Yamamoto K, Hirano S, Satoi S, Matsumoto I, Takahashi S, Morinaga S, Yoshida M, Sakuma Y, Iwamoto H, Shimizu Y, Uesaka K. Sugiura T, et al. Among authors: morinaga s. J Hepatobiliary Pancreat Sci. 2023 Nov;30(11):1249-1260. doi: 10.1002/jhbp.1353. Epub 2023 Sep 25. J Hepatobiliary Pancreat Sci. 2023. PMID: 37746781 Clinical Trial.
[Myelofibrosis].
Morinaga S, Muto Y. Morinaga S, et al. Ryoikibetsu Shokogun Shirizu. 2000;(32):425-7. Ryoikibetsu Shokogun Shirizu. 2000. PMID: 11212764 Review. Japanese. No abstract available.
Multicenter phase II trial of trastuzumab and docetaxel for HER2-positive salivary gland cancer.
Kano S, Kiyota N, Kinoshita I, Tada Y, Ijichi K, Yamazaki T, Shimizu Y, Hatanaka Y, Tsuda H, Morinaga S, Matsuno Y, Ito YM, Nishimoto N, Kobayashi K, Isoe T, Noguchi T, Homma A, Dosaka-Akita H. Kano S, et al. Among authors: morinaga s. Jpn J Clin Oncol. 2025 Oct 7;55(10):1131-1140. doi: 10.1093/jjco/hyaf106. Jpn J Clin Oncol. 2025. PMID: 40561362 Free PMC article. Clinical Trial.
Triple Combination of Recombinant Methioninase and the Anti-parasitic Drugs Ivermectin, and Chloroquine Selectively Eradicates Pancreatic Cancer Cells While Sparing Normal Fibroblasts.
Asano Y, Han Q, Li S, Mizuta K, Kang BM, Kim JS, Miyashi Y, Yamamoto N, Hayashi K, Kimura H, Miwa S, Igarashi K, Higuchi T, Morinaga S, Tsuchiya H, Demura S, Hoffman RM. Asano Y, et al. Among authors: morinaga s. Anticancer Res. 2025 Nov;45(11):4791-4802. doi: 10.21873/anticanres.17828. Anticancer Res. 2025. PMID: 41151876
Selective Synergy of the Combination of Recombinant Methioninase With Cisplatinum and Ivermectin Which Eradicates Lung-Cancer Cells but Has No Synergy and Limited Effect on Normal Fibroblasts.
Asano Y, Han Q, Li S, Mizuta K, Kang BM, Kim JS, Miyashi Y, Yamamoto N, Hayashi K, Kimura H, Miwa S, Igarashi K, Higuchi T, Morinaga S, Tsuchiya H, Demura S, Hoffman RM. Asano Y, et al. Among authors: morinaga s. Anticancer Res. 2025 Dec;45(12):5389-5398. doi: 10.21873/anticanres.17875. Anticancer Res. 2025. PMID: 41318162
Tissue Factor as a Prognostic and Therapeutic Biomarker in Resected Pancreatic Cancer.
Kamiya M, Koizume S, Kanai T, Kanemoto R, Matsushita N, Kawahara S, Kamioka Y, Murakawa M, Washimi K, Kobayashi S, Aoyama T, Ueno M, Yamamoto N, Oshima T, Morinaga S, Saito A, Miyagi Y. Kamiya M, et al. Among authors: morinaga s. Ann Surg Oncol. 2026 Jun;33(6):5080-5090. doi: 10.1245/s10434-026-19380-z. Epub 2026 Mar 12. Ann Surg Oncol. 2026. PMID: 41817932
564 results